Previous close | 3.2800 |
Open | 1.5000 |
Bid | 1.2000 |
Ask | 2.6500 |
Strike | 30.00 |
Expiry date | 2024-06-21 |
Day's range | 1.5000 - 1.9500 |
Contract range | N/A |
Volume | |
Open interest | 934 |
On June 12, 2024, Andy Sassine, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT), executed a significant transaction by selling 50,000 shares of the company.
SAN DIEGO, June 07, 2024--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, today presented Phase 1 results in healthy volunteers and Phase 1b interim data in people with CF for ARCT-032, an inhaled investigational mRNA therapeutic, at the 47th European Cystic Fibrosis Conference in G
Chief Scientific Officer & Chief Operating Officer Pad Chivukula of Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) sold 26,000 shares of the company on June 3, 2024, as reported in a recent SEC Filing.